REPL Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against Replimune Group, Inc.

Core Viewpoint - A class action lawsuit has been filed against Replimune Group, Inc. for allegedly misleading investors regarding the viability of its IGNYTE trial, which has resulted in significant stock price decline following a complete response letter from the FDA [1][2][3]. Allegations - The lawsuit claims that Replimune's management overstated the prospects of the IGNYTE trial, which the FDA deemed inadequate and not well-controlled [2]. - Defendants are accused of making materially false and misleading statements about the company's business and operations throughout the class period [2]. Stock Impact - Following the announcement of the complete response letter from the FDA on July 22, 2025, Replimune's stock price fell by $9.52 per share, representing a 77.24% decrease, closing at $2.80 per share [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs must file their papers by September 22, 2025, but they can also remain absent class members without taking action [4].